More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura

Picod, Adrien; Benhamou, Y.; Bouzid, Raïda; Veyradier, Agnès; Coppo, Paul

doi:10.1182/bloodadvances.2022009021

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to conventional antibodies, which comprise a heavy and a light chain, single-domain antibodies with only a heavy chain, known as nanobodies, have been gaining popularity in recent years. Caplacizumab, a humanized nanobody targeting the von Willebrand factor, was approved in 2019 for treating acquired thrombotic thrombocytopenic purpura [7,8]. In addition to antibodies, many non-antibody scaffolds have been developed for therapeutic applications, such as affibody, DARPin, and fynomer [9].…”

Section: Introductionmentioning

confidence: 99%

Methods for Engineering Binders to Multi-Pass Membrane Proteins

Thomas,

Chockalingam,

Chen

2023

Bioengineering

View full text Add to dashboard Cite

Numerous potential drug targets, including G-protein-coupled receptors and ion channel proteins, reside on the cell surface as multi-pass membrane proteins. Unfortunately, despite advances in engineering technologies, engineering biologics against multi-pass membrane proteins remains a formidable task. In this review, we focus on the different methods used to prepare/present multi-pass transmembrane proteins for engineering target-specific biologics such as antibodies, nanobodies and synthetic scaffold proteins. The engineered biologics exhibit high specificity and affinity, and have broad applications as therapeutics, probes for cell staining and chaperones for promoting protein crystallization. We primarily cover publications on this topic from the past 10 years, with a focus on the different formats of multi-pass transmembrane proteins. Finally, the remaining challenges facing this field and new technologies developed to overcome a number of obstacles are discussed.

show abstract

Section: Introductionmentioning

confidence: 99%